Inventor · disambiguated record
François Meyer
Also filed as: MEYER FRANCOIS · MEYER FRANCOIS G · MEYER FRANCOIS GEORGES · MEYER FRANÇOIS
18 granted patents·7 pending applications·383 citations·filing 1986–2024
94Inventor score
Files withFIRMENICH & CIE6CIBA GEIGY CORP3MEDAREX INC3SANGAMO THERAPEUTICS FRANCE3UCP GEN PHARMA AG2
Top patents by PatentIndex Score
25 records- 0193US4885166AHybrid interferonsCIBA GEIGY CORP·Filed 1986·Granted Dec 5, 1989·110 cites·8 claims
- 0289US7465451B2Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferonMEDAREX INC·Filed 2006·Granted Dec 16, 2008·11 cites·16 claims
- 0389US7179465B2Monoclonal antibodies against the interferon receptor, with neutralizing activity against type 1 interferonMEDAREX INC·Filed 2004·Granted Feb 20, 2007·27 cites·15 claims
- 0486US5919453AMonoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferonEUROP BIOTECHNOLOGIE·Filed 1993·Granted Jul 6, 1999·50 cites·22 claims
- 0581US5071761AHybrid interferonsCIBA GEIGY CORP·Filed 1989·Granted Dec 10, 1991·30 cites·11 claims
- 0679US6787634B2Isolated peptide or polypeptide of the extracellular portion of the human interferon receptor (IFN-R).MEDISUP INT NV·Filed 1999·Granted Sep 7, 2004·37 cites·5 claims
- 0777US6475983B1Water-soluble polypeptides having a high affinity for α and β interferonsMEDISUP INTERNAT N V·Filed 1991·Granted Nov 5, 2002·46 cites·31 claims
- 0875US5089400APolypeptides and process for the production thereofCIBA GEIGY CORP·Filed 1989·Granted Feb 18, 1992·20 cites·27 claims
- 0970US10383351B2Granules comprising an active substanceFIRMENICH & CIE·Filed 2018·Granted Aug 20, 2019·0 cites·16 claims
- 1069US9974323B2Process for preparing granules comprising an active substanceFIRMENICH & CIE·Filed 2012·Granted May 22, 2018·0 cites·14 claims
- 1165US2024067732A1Anti-hla-a2 antibodies and uses thereofUNIV BRITISH COLUMBIA·Filed 2023·Application pending·0 cites
- 1263US2008226647A1Monoclonal Antibodies Against The Interferon Receptor, With Neutralizing Activity Against Type I InterferonMEDAREX INC·Filed 2008·Application pending·0 cites
- 1360US11814432B2Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereofUNIV BRITISH COLUMBIA·Filed 2018·Granted Nov 14, 2023·0 cites·14 claims
- 1460US11491086B2Process for releasing an active ingredientFIRMENICH & CIE·Filed 2018·Granted Nov 8, 2022·0 cites·14 claims
- 1559US2025092145A1Chimeric antigen receptor specific for interleukin-23 receptorSANGAMO THERAPEUTICS FRANCE·Filed 2024·Application pending·0 cites
- 1658US6594394B1Fast compression and transmission of seismic dataGEOENERGY INC·Filed 1999·Granted Jul 15, 2003·43 cites·14 claims
- 1754US11981739B2Chimeric antigen receptor specific for interleukin-23 receptorSANGAMO THERAPEUTICS FRANCE·Filed 2019·Granted May 14, 2024·0 cites·20 claims
- 1853US11202463B2Encapsulated plasmolysed micro-organism particlesFIRMENICH & CIE·Filed 2014·Granted Dec 21, 2021·0 cites·14 claims
- 1952US11260001B2Process for preparing a powdered compositionFIRMENICH & CIE·Filed 2018·Granted Mar 1, 2022·0 cites·20 claims
- 2049US2013004615A1Preparation of solid capsules comprising flavoursFIRMENICH & CIE·Filed 2011·Application pending·0 cites
- 2141US9165353B2System and method for joint degradation estimation and image reconstruction in magnetic resonance imagingDAGHER JOSEPH·Filed 2012·Granted Oct 20, 2015·0 cites·12 claims
- 2240US6342373B1Process for preparing recombinant eglin, protease inhibitorUCP GEN PHARMA AG·Filed 1991·Granted Jan 29, 2002·9 cites·3 claims
- 2338US2021292389A1New car constructs comprising tnfr2 domainsSANGAMO THERAPEUTICS FRANCE·Filed 2019·Application pending·0 cites
- 2437US2012196007A1Solid capsules comprising ethanol, a carbohydrate, a salt and a coating provided by a powdering agent, process for preparing said capsules by spray-dryingMEYER FRANCOIS·Filed 2010·Application pending·0 cites
- 2536US2002142414A1Process for the preparation of protease inhibitorsUCP GEN PHARMA AG·Filed 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →